ClariTrial | Search Clinical Trials

Transscleral cyclphophotocoagulation using the Micropulse system ( IRIDEX IQ810 Laser systems, Mountain View, CA).G-Probe transscleral cyclphophotocoagulation (Iris Medical Instruments, Montain View, CA)

Centre hospitalier de l'Université de Montréal (CHUM)20 participants1 site · CanadaCompletes Dec 2034

Compare CT.gov Full analysis →

Recruiting

Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy

N/AGeographic Atrophy Secondary to Age-related Macular Degeneration

Transcorneal electrical stimulation (TES) with the OkuStim 2 SystemTranscorneal electrical stimulation (TES) with the OkuStim 2 System

Okuvision GmbH70 participants5 sites · GermanyCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

New Non-invasive Modalities for Assessing Retinal Structure and Function

N/AIschemic Optic NeuropathyBranch Retinal Artery OcclusionHemianopia

LSFG-NAVI

Randy Kardon500 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

Phase 3Leber Congenital Amaurosis 10BlindnessLeber Congenital Amaurosis

sepofarsenPlacebo IVT

Laboratoires Thea32 participants17 sites · United States, Belgium, BrazilCompletes Nov 2027

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

Phase 3Neovascular Age-related Macular DegenerationnAMD

ABP 938 8 mgAflibercept (US) 8 mg

Amgen304 participants81 sites · United States, Czechia, HungaryCompletes Jul 2027

Compare CT.gov Full analysis →

Recruiting

Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns

Phase 3Severe Diabetic Macular Oedema

Subthreshold Micropulse Laser (SML)Anti-VEGF Monotherapy (standard care)

Belfast Health and Social Care Trust264 participants22 sites · United KingdomCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

OCT in Rare Chorioretinal Diseases

N/ARetinal Artery OcclusionsPolypoidal Choroidal VasculopathyRetinal Arterial Macroaneurysm

Oregon Health and Science University150 participants1 site · United StatesCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

Phase 2Phase 3Macular DegenerationAge-Related Macular DegenerationChoroidal Neovascularization

TiespectusAflibercept

EyeBiotech Ltd.960 participants71 sites · United States, Brazil, ColombiaCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

Hyperbaric Oxygen Therapy for Optic Neuropathies

N/AOptic NeuropathyGlaucoma

Hyperbaric OxygenSham Hyperbaric Oxygen

Stanford University60 participants1 site · United StatesCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

Phase 3Macular Edema Secondary to Inflammation

KSI-101Sham Comparator

Kodiak Sciences Inc300 participants56 sites · United States, Puerto RicoCompletes Feb 2027

Compare CT.gov Full analysis →

Recruiting

Evaluation of Clinical Progression, Prognostic Factors, and Quality of Life in Patients with Age-related Macular Degeneration.

N/AAge-Related Macular Degeneration

University of Udine200 participants1 site · ItalyCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections

N/AInformed ConsentPreference, Patient

Ozurdex (dexamethasone)

Copenhagen University Hospital, Rigshospitalet200 participants1 site · DenmarkCompletes Dec 2025

Compare CT.gov Full analysis →

1–15 of 157

Explore/eye disease ophthalmology retina

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

157 results for “eye disease ophthalmology retina” · Recruiting

Page 1 of 11

Recruiting

Morphological Characteristics of the Maxillomandibular Region in a 3D Representation and the Refractive Status of the Eye

N/ARefractive Errors

No intervention; Observational study

University of Zagreb120 participants1 site · CroatiaCompletes Jun 2026

Compare CT.gov Full analysis →

Recruiting

Evaluation of Microinvasive Glaucoma Surgery: MINIject® Versus Hydrus® Microstent in Combination With Cataract Surgery

N/AGlaucomaCataract

MINIject with Cataract SurgeryHydrus Microstent with Cataract Surgery

Medical University of Graz152 participants1 site · AustriaCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2

N/AEye DiseasesVisual ImpairmentGlaucoma

Standard optometric examinationTechnology enhanced eye disease detection protocol

University of Michigan900 participants1 site · United StatesCompletes Aug 2030

Compare CT.gov Full analysis →

Recruiting

The Role of Transscleral Cyclophotocoagulation in Patients Undergoing a Boston Keratoprosthesis

N/AGlaucomaEye DiseasesCornea Disease

Centre hospitalier de l'Université de Montréal (CHUM)20 participants1 site · CanadaCompletes Dec 2034

Compare CT.gov Full analysis →

Recruiting

Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy

N/AGeographic Atrophy Secondary to Age-related Macular Degeneration

Transcorneal electrical stimulation (TES) with the OkuStim 2 SystemTranscorneal electrical stimulation (TES) with the OkuStim 2 System

Okuvision GmbH70 participants5 sites · GermanyCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

New Non-invasive Modalities for Assessing Retinal Structure and Function

N/AIschemic Optic NeuropathyBranch Retinal Artery OcclusionHemianopia

LSFG-NAVI

Randy Kardon500 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

Phase 3Leber Congenital Amaurosis 10BlindnessLeber Congenital Amaurosis

sepofarsenPlacebo IVT

Laboratoires Thea32 participants17 sites · United States, Belgium, BrazilCompletes Nov 2027

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

Phase 3Neovascular Age-related Macular DegenerationnAMD

ABP 938 8 mgAflibercept (US) 8 mg

Amgen304 participants81 sites · United States, Czechia, HungaryCompletes Jul 2027

Compare CT.gov Full analysis →

Recruiting

Phase 3Severe Diabetic Macular Oedema

Subthreshold Micropulse Laser (SML)Anti-VEGF Monotherapy (standard care)

Belfast Health and Social Care Trust264 participants22 sites · United KingdomCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

OCT in Rare Chorioretinal Diseases

N/ARetinal Artery OcclusionsPolypoidal Choroidal VasculopathyRetinal Arterial Macroaneurysm

Oregon Health and Science University150 participants1 site · United StatesCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

Phase 2Phase 3Macular DegenerationAge-Related Macular DegenerationChoroidal Neovascularization

TiespectusAflibercept

EyeBiotech Ltd.960 participants71 sites · United States, Brazil, ColombiaCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

Hyperbaric Oxygen Therapy for Optic Neuropathies

N/AOptic NeuropathyGlaucoma

Hyperbaric OxygenSham Hyperbaric Oxygen

Stanford University60 participants1 site · United StatesCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

Phase 3Macular Edema Secondary to Inflammation

KSI-101Sham Comparator

Kodiak Sciences Inc300 participants56 sites · United States, Puerto RicoCompletes Feb 2027

Compare CT.gov Full analysis →

Recruiting

Evaluation of Clinical Progression, Prognostic Factors, and Quality of Life in Patients with Age-related Macular Degeneration.

N/AAge-Related Macular Degeneration

University of Udine200 participants1 site · ItalyCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections

N/AInformed ConsentPreference, Patient

Ozurdex (dexamethasone)

Copenhagen University Hospital, Rigshospitalet200 participants1 site · DenmarkCompletes Dec 2025

Compare CT.gov Full analysis →

1–15 of 157